IGF-II Transgenic Mice and Colon Cancer
Author Information
Author(s): Diehl Daniela, Oesterle Doris, Elmlinger Martin W, Hoeflich Andreas, Wolf Eckhard, Lahm Harald
Primary Institution: Ludwig-Maximilians University
Hypothesis
Does IGF-II affect different stages of tumorigenesis in colon cancer?
Conclusion
IGF-II promotes the growth of aberrant crypt foci and tumors in colon cancer without affecting the number of tumors.
Supporting Evidence
- IGF-II transgenic mice had significantly more aberrant crypt foci than wild-type mice after DMH treatment.
- Serum IGF-II levels correlated with tumor volume in IGF-II transgenic mice.
- Histological analysis showed that most tumors were adenomas, with some classified as adenocarcinomas.
Takeaway
This study looked at mice with a special gene that makes them produce more IGF-II, a growth factor. They found that these mice had more early signs of colon cancer but not more actual tumors.
Methodology
The study used IGF-II transgenic and non-transgenic mice treated with 1,2-dimethylhydrazine to evaluate tumor development and ACF.
Potential Biases
Potential bias in observer scoring of tumors and ACF.
Limitations
The study did not assess the long-term effects of IGF-II on tumor development beyond the observed time points.
Participant Demographics
Female NMRI mice, both transgenic and non-transgenic.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website